<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000427</url>
  </required_header>
  <id_info>
    <org_study_id>P50AR044855</org_study_id>
    <secondary_id>P50AR044855</secondary_id>
    <secondary_id>NIAMS-015</secondary_id>
    <nct_id>NCT00000427</nct_id>
  </id_info>
  <brief_title>Effects of Parathyroid Hormone in Men With Osteoporosis</brief_title>
  <official_title>Anabolic Actions of Parathyroid Hormone in Osteoporotic Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      Alendronate is a drug that blocks or reduces bone loss, while parathyroid hormone (PTH)&#xD;
      stimulates the formation of new bone. The purpose of this study is to compare the&#xD;
      bone-building effects of PTH alone, alendronate alone, and both PTH and alendronate in men&#xD;
      with osteoporosis over a two-and-a-half year period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoporosis causes bones to weaken and break more easily. Alendronate is used to treat or&#xD;
      prevent osteoporosis. PTH is a protein hormone that increases the calcium and phosphorus&#xD;
      release from bone, leading to formation of new bone. This study will examine the changes in&#xD;
      bone density measured at multiple places in the skeleton and changes in chemicals in the body&#xD;
      that indicate bone breakdown and bone formation. The study will indicate whether some&#xD;
      breakdown of bone is required for PTH to have an overall bone-building effect in men.&#xD;
&#xD;
      Participants will be randomly assigned to receive PTH alone by daily injection under the&#xD;
      skin, alendronate alone taken by mouth, or both PTH and alendronate. The study will last 2.5&#xD;
      years. All participants will receive some form of treatment for osteoporosis. Blood, urine,&#xD;
      and bone density tests will be performed at 6-month intervals. During the first 6 months,&#xD;
      participants will come in for additional study visits.&#xD;
&#xD;
      Participants who complete the initial 2.5 years of their assigned treatment will be eligible&#xD;
      for a 12 month extension to monitor bone density and bone turnover after PTH is stopped.&#xD;
      Participants who were receiving alendronate will continue taking alendronate. The goal of&#xD;
      this extension is to determine what happens to bone density and turnover after PTH is stopped&#xD;
      and whether alendronate is needed to prevent loss of PTH-induced bone gain.&#xD;
&#xD;
      Participants who complete the 12 month extension while on their assigned treatment will be&#xD;
      eligible for a second 12 month extension in which all participants receive PTH therapy.&#xD;
      Participants who have been receiving alendronate continue taking alendronate. The goal of the&#xD;
      second extension is to determine if responsiveness to PTH is enhanced by a 12 month&#xD;
      suspension of PTH treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1999</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>81</enrollment>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parathyroid hormone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Bone density of the spine or femoral neck two standard deviations below the mean of&#xD;
             young adult men&#xD;
&#xD;
          -  Normal renal and liver function tests, normal serum testosterone level, normal vitamin&#xD;
             D and PTH levels&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant cardiac, renal, hepatic, or malignant disease.&#xD;
&#xD;
          -  Disorders (e.g., Paget's disease, hyperthyroidism, hyperparathyroidism) or drugs&#xD;
             (e.g., steroids, anticonvulsants, lithium, bisphosphonates, calcitonin, fluoride)&#xD;
             known to affect bone metabolism&#xD;
&#xD;
          -  Active peptic ulcer disease or severe reflux&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>46 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel S. Finkelstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med. 1994 Dec 15;331(24):1618-23. doi: 10.1056/NEJM199412153312404.</citation>
    <PMID>7969342</PMID>
  </reference>
  <reference>
    <citation>Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003 Sep 25;349(13):1216-26. doi: 10.1056/NEJMoa035725. Epub 2003 Sep 20.</citation>
    <PMID>14500805</PMID>
  </reference>
  <results_reference>
    <citation>Finkelstein JS, Leder BZ, Burnett SM, Wyland JJ, Lee H, de la Paz AV, Gibson K, Neer RM. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab. 2006 Aug;91(8):2882-7. doi: 10.1210/jc.2006-0190. Epub 2006 May 9.</citation>
    <PMID>16684825</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>January 18, 2000</study_first_submitted>
  <study_first_submitted_qc>January 18, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2000</study_first_posted>
  <last_update_submitted>December 6, 2013</last_update_submitted>
  <last_update_submitted_qc>December 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Joel S. Finkelstein, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Parathyroid Hormone (PTH)</keyword>
  <keyword>Alendronate</keyword>
  <keyword>Bone metabolism</keyword>
  <keyword>Bone mineral density (BMD)</keyword>
  <keyword>Bone loss</keyword>
  <keyword>Postmenopausal osteoporosis</keyword>
  <keyword>Osteoporosis in men</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Parathyroid Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

